Growth is the process to increase cell mass and size by accumulation of newly synthesized proteins. It is increasingly appreciated as an important process in tumorigenesis, which is required to support the rapid cancer cell proliferation (an increase in cell number). The rate of protein synthesis is determined by both translational initiation and the abundance of ribosomes. Producing ribosomes or ribosome biogenesis involves several hundred genes and all three RNA polyrinerasesand accounts for 90% nuclear transcription. Ribosome biogenesis is highly energy-consuming and is tightly controlled by growth factors and nutrients. It has been long known that, in cancer cells, components of the translational machinery are deregulated or misexpressed. Several tumor suppressors and proto-oncogenes, such as the retinoblastoma (Rb) protein, p53, PTEN and Myc, have been shown to target ribosome biogenesis. Rapamycin is a promising new anticancer drug currently under large clinical trials. It is well tolerated and has shown excellent efficacy for many human cancers. We have recently obtained evidence that inhibition of ribosome biogenesis is crucial for rapamycin to inhibit cell growth, and discovered several new mechanisms for rapamycin to inhibit ribosome biogenesis. In this proposal, we will investigate the regulatory mechanisms of ribosome biogenesis, nucleolar size control and rapamycin inhibition. Accomplishment of these goals should advance the understanding of growth control, tumorigenesis and the mechanism of action by rapamycin. Additionally, such studies may lead to more effective anticancer therapeutic strategies and help identify new cancer drug targets in this important yet poorly studied area in cancer therapeutics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Medicine & Dentistry of NJ
Schools of Medicine
United States
Zip Code
Zhang, Hong; Li, Xiaoxing; Yang, Yang et al. (2017) Significance and Mechanism of Androgen Receptor (AR) Overexpression and AR-mTOR Crosstalk in Hepatocellular Carcinoma. Hepatology :
Zhang, Yanjie; Huang, Bo; Wang, Hui-Yun et al. (2017) Emerging Role of MicroRNAs in mTOR Signaling. Cell Mol Life Sci 74:2613-2625
Che, Meixia; Wang, Ren; Li, Xiaoxing et al. (2016) Expanding roles of superoxide dismutases in cell regulation and cancer. Drug Discov Today 21:143-149
Yang, X-Z; Li, X-X; Zhang, Y-J et al. (2016) Rab1 in cell signaling, cancer and other diseases. Oncogene 35:5699-5704
Li, Yue; Tsang, Chi Kwan; Wang, Suihai et al. (2016) MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription. Hepatology 63:1928-42
Wu, Tzung-Ju; Wang, Xiaowen; Zhang, Yanjie et al. (2015) Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. Cell Rep 11:446-59
Zhang, Yanjie; Wang, Xiaowen; Qin, Xiaoyu et al. (2015) PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine 2:1944-56
Meng, Ling-hua; Zheng, X F Steven (2015) Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin 36:1163-9
Tsang, Chi Kwan; Liu, Yuan; Thomas, Janice et al. (2014) Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun 5:3446
Thomas, Janice D; Zhang, Yan-Jie; Wei, Yue-Hua et al. (2014) Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell 26:754-69

Showing the most recent 10 out of 18 publications